Sustained Release Ocular Drug Delivery Systems Market, 2014-2024
Nov 27, 2014, 05:00 ET
LONDON, Nov. 27, 2014 /PRNewswire/ -- INTRODUCTION
Given the intricacy of the anatomy and physiology of the eye, it is quite challenging to deliver an ophthalmic drug effectively to a specific ocular site. Several barriers have to be overcome for successful ocular drug delivery. For example, dilution of a drug by tears, clearance of a drug by the lymphatic system of conjunctiva, drug permeation issues with respect to the cornea, sclera, choroid etc. Accordingly, different drug delivery systems have been devised for controlled release of drugs to various parts of the eye. Intravitreal implants for delivery of drugs to the posterior segment of the eye are already commercially available. Moreover, a number of companies are developing injectable particulate systems for controlled drug delivery to treat such diseases. This has been the primary focus for sustained delivery of drugs till date. However, industry and academia are working on novel implants, including drug-eluting contact lenses and punctal plugs, for treatment of anterior segment diseases such as glaucoma and conjunctivitis.
The 'Sustained Release Ocular Drug Delivery Systems, 2014 - 2024' report provides an extensive study of the emerging market of implants and particulate drug delivery systems (DDS) for ophthalmic diseases. The focus of this study is on commercial implants and those under development, their applications and the likely mid-term and long-term evolution. It is widely anticipated that the ophthalmic drug delivery systems market has tremendous potential. The sustained drug delivery systems provide improved retention time compared to topical applications and offer convenience over regular intravitreal injections, mainly for posterior eye diseases.
SCOPE OF THE REPORT
The report covers various aspects such as technological progress, product pipeline, industry and academic research programs to assess new evolving opportunities.
One of the key objectives of this report is to understand the current and future state of the ophthalmic sustained drug delivery market. This is done by analysing the following:
- Ophthalmic sustained release drug delivery systems currently available in the market
- Ophthalmic sustained release drug delivery systems currently in the pipeline
- Leading technology providers and drug delivery systems developers
- Most commonly targeted indications and drugs being delivered
- Size of target consumer segments
The base year for the report is 2013. The report provides market forecasts for the following two time horizons: 2014 - 2019 and 2019 - 2024, respectively. We have discussed, in detail, key drivers behind the likely growth of ophthalmic drug delivery systems market. The research, analysis and insights presented in this report include the sales potential of various marketed and late stage pipeline ocular sustained drug delivery system products based on the current expected launch timelines, adoption rates and the estimated end-use price points. The figures mentioned in this report are in USD, unless otherwise specified.
1. Vitrasert, launched in 1996, was the first ocular implant. It was, however, taken off the market in 2013. Only three more implants have received regulatory approval since 1996; these are Retisert, Ozurdex and Iluvien.
2. Out of 42 sustained release ocular drug delivery systems (marketed / under development), 3 are already marketed for specific indications and 14 are in Phase II or Phase III of development.
3. Diabetic Macular Edema (DME) will provide the much needed boost to the sustained release ocular drug delivery systems market in the short-term. The potential in the market is huge with a high target population, which is growing significantly due to the rise in cases of diabetes.
4. In the mid to long term, the growth will be boosted by launch of sustained release systems for glaucoma and AMD. At least three companies have sustained release systems delivering prostaglandin analogues in phase II development and one in phase I/II for the treatment of glaucoma and ocular hypertension.
5. The overall market is likely to be more than USD 1 billion in the coming decade. The opportunity could be much higher in the outer years, especially driven by the regulatory approval of implants for delivery of biologics.
Most of the data presented in this report has been gathered by secondary research. We have also conducted interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will shape up across different regions and drug segments. Where possible, the available data has been checked for accuracy from multiple sources of information.
The secondary sources of information include
- Annual reports
- Investor presentations
- SEC filings
- Industry databases
- News releases from company websites
- Government policy documents
- Other analysts' opinion reports
While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.
Chapter 2 provides an executive summary of the insights captured in our research. The summary offers a high level view on where the ophthalmic drug delivery system market is headed in the mid-long term.
Chapter 3 provides a general introduction to the ophthalmic drug delivery market. We have discussed, in detail, anatomy of the eye, types of ocular drug delivery implants and various ocular diseases being targeted.
Chapter 4 provides an overview of the ophthalmic drug delivery systems market with respect to the available marketed technologies and companies active in the field. The analysis also extends to pipeline analysis with respect to phase of development, system type, indication targeted and drug being eluted.
Chapter 5 presents profiles of eight ophthalmic sustained release drug delivery systems with information on their technology, development history, principal features, current status of development, pricing and sales (for marketed products). We have also presented our sales forecast of each of these systems during short-mid term (2014 - 2019) and long term (2019 - 2024).
Chapter 6 reviews the leading companies which are active in the area of ophthalmology sustained release drug delivery technology. Each company profile includes information such as financial performance, marketed / pipeline ophthalmic products, recent developments and future growth plans.
Chapter 7 provides our analysis of the strengths, weaknesses, opportunities and threats in the ophthalmology drug delivery systems market, capturing the key elements likely to influence future growth.
Chapter 8 is a collection of transcripts based on our discussion with some of the leading players in the industry.
Chapter 9 summarizes the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.
Chapters 10 and 11 are appendices, which provide tabulated data and a list of companies mentioned in the report.
Download the full report: https://www.reportbuyer.com/product/2082021/
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
For more information:
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sustained-release-ocular-drug-delivery-systems-market-2014-2024-300002094.html
Share this article